Deuruxolitinib phosphate is under clinical development by Concert Pharmaceuticals and currently in Phase III for Alopecia Areata. According to GlobalData, Phase III drugs for Alopecia Areata have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Deuruxolitinib phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Deuruxolitinib phosphate overview
Deuruxolitinib phosphate (CTP-543, Deuterated Ruxolitinib) is under development for the treatment of moderate to severe alopecia areata. It is a deuterium-modified analog of ruxolitinib administered orally. It acts by targeting the Janus kinases (JAK1 and JAK2). It is developed based on the DCE (deuterated chemical entity) platform.
Concert Pharmaceuticals overview
Concert Pharmaceuticals (Concert Pharma) is a late-stage clinical biotechnology company. It discovers and develops drugs for impacted patient care and addresses medical needs. The company develops its products using its deuterated chemical entity (DCE) platform for the treatment of autoimmune dermatological conditions, which includes alopecia areata. The alopecia areata occurs when the immune system attacks the hair follicles and is characterized as non-scarring hair loss. It also develops CTP-543, which is an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of adults with moderate to severe alopecia areata. The company has operations in the US, the UK and Ireland. Concert Pharma is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Deuruxolitinib phosphate’s drug-specific PTSR and LoA scores, buy the report here.